John C.M. Farquhar Sells 27,230 Shares of Heartflow (NASDAQ:HTFL) Stock

Key Points

• CEO John C.M. Farquhar sold 27,230 Heartflow shares at an average price of $50, generating $1.36 million. The Rule 10b5-1 transaction reduced his direct ownership by 7.02% to 360,814 shares.
• Heartflow shares recently traded near $49.89, close to their 12-month high of $51.19, with a $4.34 billion market capitalization. The stock has risen substantially above its 50-day and 200-day moving averages.
• Heartflow reported quarterly revenue of $64.08 million, up 47.7% year over year, and an adjusted loss of $0.07 per share that beat expectations. Analysts maintain a Moderate Buy consensus with an average price target of $43.43, below the current share price.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John C.M. Farquhar sold 27,230 shares of the company's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $50.00, for a total value of $1,361,500.00. Following the sale, the chief executive officer directly owned 360,814 shares in the company, valued at approximately $18,040,700. This represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Tuesday, August 18th, John C.M. Farquhar sold 32,676 shares of Heartflow stock. The stock was sold at an average price of $45.00, for a total transaction of $1,470,420.00.
• On Friday, August 14th, John C.M. Farquhar sold 15,560 shares of Heartflow stock. The shares were sold at an average price of $39.06, for a total transaction of $607,773.60.
• On Monday, August 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.31, for a total value of $638,730.22.
• On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.75, for a total transaction of $626,095.50.
• On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00.
• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.50, for a total transaction of $643,017.00.

Heartflow Stock Performance

Shares of HTFL traded down $0.31 during mid-day trading on Tuesday, reaching $49.89. 1,748,540 shares of the company's stock traded hands, compared to its average volume of 1,534,533. The business's 50-day moving average price is $31.00 and its 200-day moving average price is $28.47. The stock has a market capitalization of $4.34 billion and a P/E ratio of -27.26. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $51.19.

Heartflow (NASDAQ:HTFL - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The firm had revenue of $64.08 million for the quarter. The business's quarterly revenue was up 47.7% on a year-over-year basis. Equities research analysts anticipate that Heartflow, Inc. will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. XXEC Inc. purchased a new position in shares of Heartflow in the second quarter worth approximately $2,524,764,000. Sei Investments Co. boosted its stake in Heartflow by 342.5% in the 1st quarter. Sei Investments Co. now owns 67,048 shares of the company's stock worth $1,631,000 after purchasing an additional 51,895 shares during the period. Quantinno Capital Management LP purchased a new position in Heartflow during the 1st quarter worth approximately $1,734,000. Handelsbanken Fonder AB purchased a new stake in shares of Heartflow in the second quarter valued at $910,000. Finally, Walleye Capital LLC acquired a new stake in shares of Heartflow in the second quarter worth $8,760,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on HTFL. Canaccord Genuity Group increased their target price on shares of Heartflow from $37.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, August 14th. Freedom Capital upgraded shares of Heartflow to a "strong-buy" rating in a research report on Tuesday, June 30th. JPMorgan Chase & Co. raised their price objective on shares of Heartflow from $35.00 to $45.00 and gave the company an "overweight" rating in a research note on Friday, August 14th. Robert W. Baird set a $45.00 target price on Heartflow in a research report on Friday, August 14th. Finally, Benchmark restated a "buy" rating on shares of Heartflow in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $43.43.

About Heartflow

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source